Skip to main content

Table 1 All of the long non coding RNAs involved in tumor progressions among Iranian patients

From: Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview

Study (et al.) Year Type Gene Population Results
Shahryari [37] 2014 ESCC SOX2OT 36 N/Ta Over expression
Rezaei [45] 2016 Esophageal, ovarian, cervical, breast, sarcoma, colon, and melanoma LINC-ROR 27 N/T Esophageal, ovarian, and cervical cancers had over expressions while breast, sarcoma, colon, and melanoma had under expressions
Sahebi [49] 2016 ESCC LINC-ROR 30 N/T Over expression
Rahimnia [51] 2018 ESCC lnc-POU3F3 32 patients
32 controls
Over expression
Razavi [56] 2019 ESCC lnc-PCAT-1 75 N/T Over expression
Bayat [58] 2018 Prostate Prcat17.3, Prcat38, Cat2184.4 30 N/T Prcat17.3 and Prcat38 over expressions and Cat2184.4 under expression
Taheri [60] 2017 Prostate HOTAIR 128 patients
250 controls
Polymorphism was correlated with tumor progression
Taheri [64] 2017 Prostate ANRIL 125 patients
220 controls
Polymorphism was correlated with tumor progression
Sattarifard [66] 2017 Prostate PRNCR1 178 patients
180 BPHb
Polymorphism was correlated with tumor progression
Yazarlou [83] 2018 Bladder LINC00355, UCA1-203, MALAT1, and UCA1-201 59 patients
24 controls
LINC00355, UCA1-203, and MALAT1 over expressions. UCA1-201 under expression
Farhangian [88] 2018 Gastric SOX2OT 33 N/T Under expression
Hajjari [90] 2013 Gastric HOTAIR 31 N/T Over expression
Emadi-Andani [91] 2014 Gastric HOTAIR 60 N/T Over expression
Baratieh [97] 2017 Gastric PlncRNA-1 and TUG1 70 N/T Over expression
Aminian [103] 2019 Gastric GAS5 130 patients
230 controls
Polymorphism was correlated with tumor progression
Kangarlouei [106] 2019 Gastric ANRIL and ANRASSF1 39 N/T Over expression
Iranpour [111] 2016 Breast SOX2OT, PTPRG-AS1, ANRASSF1, and ANRIL 38 N/T Over expression
Hassanzarei [114] 2017 Breast HOTAIR 220 patients
231 controls
Polymorphism was correlated with tumor progression
Hassanzarei [118] 2017 Breast H19 230 patients
240 controls
Polymorphism was correlated with tumor progression
Safari [119] 2019 Breast H19 111 patients
130 controls
Polymorphism was correlated with tumor progression
Abdollahzadeh [120] 2019 Breast H19 150 patients
100 controls
Polymorphism was correlated with tumor progression
Arshi [130] 2018 Breast MALAT1, SRA, NEAT1, and GAS5 23 patients
15 controls
MALAT1, SRA, and NEAT1 over expressions. GAS5 under expression
Soleimanpour [135] 2018 Breast PRNCR1 30 N/T Over expression
Ravanbakhsh [138] 2019 Breast lncUSMycN 52 N/T Over expression
Rezanejad Bardaji [140] 2018 Colorectal ZEB1-AS1 32 N/T Over expression
Kazemzadeh [143] 2017 Colorectal LOC100287225 30 N/T Under expression
Kazemzadeh [142] 2016 Colorectal LOC100287225 39 N/T Under expression
Rezanejad bardaji [144] 2018 Colorectal VIM-AS1 35 N/T Over expression
Hashemi [146] 2016 ALL lnc-LAMC2-1:1 110 patients
120 controls
Polymorphism was correlated with tumor progression
Esfandi [150] 2018 Lung OIP5-AS 32 N/T Under expression
  1. aTumor tissues and normal margins
  2. bBenign prostatic hyperplasia